Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials

      This paper is only available as a PDF. To read, Please Download here.


      Background: Heart failure in blacks has been associated with a poorer prognosis than in whites. In such diseases as hypertension, blacks show pathophysiological differences and respond differently to some therapies than whites. The aim of this study is to evaluate the clinical characteristics and response to therapy of black compared with white patients with heart failure.
      Methods and Results: In the first Vasodilator-Heart Failure Trial (V-HeFT I), 180 black male patients were compared with 450 white male patients for baseline characteristics, prognosis, and response to therapy. In V-HeFT II, the same comparisons were made for 215 black and 574 white male patients, including an analysis stratified by the presence or absence of a history of hypertension. In both trials, black patients had a lower incidence of coronary artery disease, greater incidence of previous hypertension, and a greater cardiothoracic ratio (P < .05) than white patients. In V-HeFT II, plasma norepinephrine levels were significantly less in blacks; plasma renin activity was less only in blacks with a history of hypertension. Overall mortality or hospitalization for congestive heart failure did not differ between blacks and whites in the placebo group in V-HeFT I. However, the mortality of black patients receiving hydralazine plus isosorbide dinitrate (H-I) was reduced (P = .04) in V-HeFT I, whereas white patients showed no difference from placebo. In V-HeFT II, only white patients showed a mortality reduction from enalapril therapy compared with H-I therapy (P = .02). Whites also showed evidence of greater blood pressure reduction and enhanced regression of cardiac size in response to enalapril. When stratified by history of hypertension in V-HeFT II, only whites with a history of hypertension, who had greater renin levels, showed significant mortality reduction with enalapril compared with H-I therapy. Hospitalization rates did not differ between treatment groups in either study.
      Conclusion: Whites and blacks showed differences in cause, neurohormonal stimulation, and pharmacological response in heart failure. This retrospective analysis suggests angiotensinconverting enzyme inhibitors are particularly effective in whites, and the H-I combination can be equally effective in blacks. Prospective trials involving large numbers of black patients are needed to further clarify their response to therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ghali JK
        • Cooper R
        • Ford E
        Trends in hospitalization rates for heart failure in the United States, 1973–1986: evidence for increasing population prevalence.
        Arch Intern Med. 1990; 150: 769-773
        • Alexander M
        • Grumbach K
        • Selby J
        • Brown AF
        • Washington E
        Hospitalization for congestive heart failure-explaining racial differences.
        JAMA. 1995; 274: 1037-1042
        • Whittle J
        • Conigliaro J
        • Good CB
        • Lofgren RP
        Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs Medical System.
        N Engl J Med. 1993; 329: 621-627
        • Gillum RF
        Heart failure in the United States, 1970–1985.
        Am Heart J. 1987; 113: 1043-1045
        • Gillum RF
        Pathophysiology of hypertension in blacks and whites.
        Hypertension. 1979; 1: 468-475
        • Cohn JN
        • Archibald DG
        • Ziesche S
        • Franciosa JA
        • Harston WE
        • Tristani FE
        • Dunkman WB
        • Jacobs W
        • Francis GS
        • Flohr KH
        • Goldman S
        • Cobb FR
        • Shah PM
        • Saunders R
        • Fletcher RD
        • Loeb HS
        • Hughes VC
        • Baker B
        Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT).
        N Engl J Med. 1986; 314: 1547-1552
        • Cohn JN
        • Johnson G
        • Ziesche S
        • Cobb F
        • Francis G
        • Tristani F
        • Smith R
        • Dunkman WB
        • Loeb H
        • Wong M
        • Bhat G
        • Goldman S
        • Fletcher RD
        • Doherty J
        • Hughes CV
        • Carson P
        • Cintron G
        • Shabetai R
        • Haakenson C
        A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
        N Engl J Med. 1991; 325: 303-310
        • Veterans Administration Co-Operative Study Group on Antihypertensive Agents
        Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide.
        Br J Clin Pharmacol. 1982; 14: 97-101
        • Saunders E
        • Weir MR
        • Kong BW
        • Hollifield J
        • Gray J
        • Vertes V
        • Sowers JR
        • Zemel MB
        • Curry C
        • Schoenberger J
        • Wright JT
        • Kirkendall W
        • Conradi EC
        • Jenkins P
        • McLean B
        • Massie B
        • Berenson G
        • Flamenbaum W
        A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.
        Arch Intern Med. 1990; 150: 1707-1713
        • Passon PG
        • Beuler JD
        A simplified radiometric assay for norepinephrine and epinephrine.
        Anal Biochem. 1973; 51: 618-631
        • Sealey JE
        Plasma renin activity and plasma prorenin assays.
        Clin Chem. 1991; 37: 1811-1819
        • Dries DL
        • Exner DV
        • Gersh BJ
        • Cooper HA
        • Carson PE
        • Domanski MJ
        Racial differences in the outcome of left ventricular dysfunction.
        N Engl J Med. 1999; 340: 609-616
        • Peniston RL
        • Lu DY
        • Papademetriou V
        • Fletcher RD
        Severity of coronary artery disease in black and white veterans and likelihood of revascularization.
        J Am Coll Cardiol. 1994; 23 (abstr): 299A
        • Joint National Committee
        The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.
        Arch Intern Med. 1985; 144: 1045-1057
        • Bourassa MG
        • Gurne O
        • Bangdiwala SI
        • Ghali JK
        • Young JB
        • Rousseau M
        • Johnstone DE
        • Yusuf S
        Natural history and patterns of current practice in heart failure.
        J Am Coll Cardiol. 1993; 22: 14-19
        • Cohn JN
        • Archibald DG
        • Francis GS
        • Ziesche S
        • Franciosa JA
        • Harston WE
        • Tristani FE
        • Dunkman WB
        • Jacobs W
        • Flohr KH
        • Goldman S
        • Cobb FR
        • Shah PM
        • Saunders R
        • Fletcher RD
        • Loeb HS
        • Hughes VC
        • Baker B
        Veterans Administration Cooperative Study on vasodilator therapy of heart failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
        Circulation. 1987; 75: 49-54
        • Johnson G
        • Carson P
        • Francis GS
        • Cohn JN
        • for the VHeFT VA Cooperative Studies Group
        Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril: Veterans Affairs Cooperative Study on Vasodilator Therapy on Heart Failure (V-HeFT II).
        Circulation. 1993; 87: 32-39
        • Ghali JK
        • Kadakia S
        • Cooper R
        • Ferlinz J
        Precipitating factors leading to decompensation of heart failure: traits among urban blacks.
        Arch Intern Med. 1988; 148: 2013-2016
        • Cody RJ
        • Court AB
        • Schaer GL
        • Laragh JH
        • Sealey JE
        • Feldschuh J
        Sodium and water balance in chronic congestive heart failure.
        J Clin Invest. 1986; 77: 1441-1452
        • Anand IS
        • Ferrari R
        • Kalra GS
        • Wahi PL
        • Poole-Wilson PA
        • Harris PC
        Edema of cardiac origin.
        in: Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive heart failure. ed 2. Circulation. 80. 1989: 299-305
        • Kaplan NM
        • Kem DC
        • Holland OB
        • Kramer NJ
        • Higgins J
        • Gomez-Sanchez C
        The intravenous furosemide test: A simple way to evaluate renin responsiveness.
        Ann Intern Med. 1976; 84: 639-645
        • Cohn JN
        • Johnson GR
        • Shabetai R
        • Loeb H
        • Tristani F
        • Rector T
        • Smith R
        • Fletcher R
        • for the V-HeFT VA Cooperative Studies Group
        Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure.
        Circulation. 1993; 87: 5-16
        • Mills PJ
        • Dimsdale JG
        • Ziegler MG
        • Neleson RA
        Racial differences in epinephrine and beta adrenergic receptors.
        Hypertension. 1995; 25: 88-91
        • Pratt JH
        • Menatunga AK
        • Bowsher RR
        • Henry BP
        The interaction of norepinephrine excretion with blood pressure and race in children.
        J Hypertens. 1992; 10: 93-96
        • Veterans Administration Cooperative Study Group on Antihypertensive Agents
        Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension-I. Results of short-term titration with emphasis on racial differences in response.
        JAMA. 1982; 248: 1996-2003
        • Veterans Administration Cooperative Study Group on Antihypertensive Agents
        Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension II. Results of long-term therapy.
        JAMA. 1982; 248: 2004-2011
        • Cody RJ
        • Laragh JH
        • Case DB
        • Atlas SA
        Renin system activity as a determinant of response to treatment in hypertension and heart failure.
        Hypertension. 1983; 5: 36-42
        • Pierpont GL
        • Cohn JN
        • Franciosa JA
        Combined oral hydralazine-nitrate therapy in left ventricular failure.
        in: Hemodynamic equivalency to sodium nitroprusside. ed 2. Chest. 73. 1978: 8-13
        • Bauer JA
        • Fung H-L
        Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure.
        Circulation. 1991; 84: 35-39
        • Münzel T
        • Kurz S
        • Rajagopalan S
        • Martin T
        • Berrington WR
        • Thompson JA
        • Fruman BA
        • Harrison DG
        Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase.
        J Clin Invest. 1996; 98: 1465-1470
        • Gogia H
        • Mehra A
        • Parikh S
        • Raman M
        • Uppal JA
        • Johnson JV
        • Elkayam U
        Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
        J Am Coll Cardiol. 1995; 26: 1575-1580